Ewa Harasim-Symbor

Dr. Ewa Harasim-Symbor

Department of Physiology, Medical University of Bialystok
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
KSKlaudia Sztolsztener
Klaudia Sztolsztener
ACAdrian Chabowski
Adrian Chabowski
EHEwa Harasim-Symbor
Ewa Harasim-Symbor
PBPatrycja Bielawiec
Patrycja Bielawiec
KKKarolina Konstantynowicz-Nowicka
Karolina Konstantynowicz-Nowicka
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excessive lipid deposition. Lipid metabolism disturbances are possibly associated with hepatocyte inflammation development and oxidative balance impairment. The aim of our experiment was to examine the first moment when changes in plasma and liver arachidonic acid (AA) levels as a pro-inflammatory precursor may occur during high-fat diet (HFD)-induced NAFLD development. Wistar rats were fed a diet rich in fat for five weeks, and after each week, inflammation and redox balance parameters were evaluated in the liver. The AA contents in lipid fractions were assessed by gas–liquid chromatography (GLC). Protein expression relevant to inflammatory and lipogenesis pathways was determined by immunoblotting. The oxidative system indicators were determined with assay kits. Our results revealed that a high-fat diet promoted an increase in AA levels, especially in the phospholipid (PL) fraction. Importantly, rapid inflammation development via increased inflammatory enzyme expression, elevated lipid peroxidation product content and oxidative system impairment was caused by the HFD as early as the first week of the experiment. Based on these results, we may postulate that changes in AA content may be an early indicator of inflammation and irreversible changes in NAFLD progression.

4 March 2020 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PBPatrycja Bielawiec
Patrycja Bielawiec
EHEwa Harasim-Symbor
Ewa Harasim-Symbor
ACAdrian Chabowski
Adrian Chabowski
Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of triacylglycerols (TAGs) in a diet also evokes adipocyte hyperplasia and subsequent accumulation of lipids in peripheral organs (liver, cardiac muscle). Therefore, new therapeutic methods are constantly sought for the prevention, treatment and alleviation of symptoms of the above mentioned diseases. Currently, much attention is paid to Cannabis derivatives-phytocannabinoids, which interact with the endocannabinoid system (ECS) constituents. Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the most abundant compounds of Cannabis plants and their therapeutic application has been suggested. CBD is considered as a potential therapeutic agent due to its anti-inflammatory, anti-oxidant, anti-tumor, neuroprotective, and potential anti-obesity properties. Therefore, in this review, we especially highlight pharmacological properties of CBD as well as its impact on obesity in different tissues.

20 February 2010 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GCGrzegorz Chocian
Grzegorz Chocian
ACAdrian Chabowski
Adrian Chabowski
MŻMałgorzata Żendzian-Piotrowska
Małgorzata Żendzian-Piotrowska
EHEwa Harasim-Symbor
Ewa Harasim-Symbor
BŁBartłomiej Łukaszuk
Bartłomiej Łukaszuk
JGJan Górski
Jan Górski

22 July 2015 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ABArend Bonen
Arend Bonen
SJSwati S. Jain
Swati S. Jain
LSLaelie A. Snook
Laelie A. Snook
XHXiao-Xia Han
Xiao-Xia Han
YYYuko Yoshida
Yuko Yoshida
GHGraham P. Holloway
Graham P. Holloway

5 June 2017 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
HMHanna Myśliwiec
Hanna Myśliwiec
Anna BaranAnna Baran
Anna Baran
EHEwa Harasim-Symbor
Ewa Harasim-Symbor
PMPiotr Myśliwiec
Piotr Myśliwiec
AMAnna Justyna Milewska
Anna Justyna Milewska
Iwona FlisiakIwona Flisiak
Iwona Flisiak
Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas–liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls. FAs were grouped according to their biologic properties to saturated FA (SFA), unsaturated FA (UFA), monounsaturated FA (MUFA), n-3 polyunsaturated FA (n-3 PUFA) and n-6 PUFA. Generally, patients characteristic included: Psoriasis Area and Severity Index (PASI), Body Mass Index, inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidity. We have observed highly abnormal FAs pattern in psoriatic patients both with and without obesity compared to the control group. We have demonstrated association of PASI with low levels of circulating DHA, n-3 PUFA (p = 0.044 and p = 0.048, respectively) and high percent of MUFA (p = 0.024) in the non-obese psoriatic group. The SFA/UFA ratio increased with the duration of the disease (p = 0.03) in all psoriatic patients. These findings indicate abnormal FAs profile in psoriasis which may reflect metabolic disturbances and might play a role in the psoriatic comorbidity.

17 December 2016 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
HMHanna Myśliwiec
Hanna Myśliwiec
Anna BaranAnna Baran
Anna Baran
EHEwa Harasim-Symbor
Ewa Harasim-Symbor
BCBarbara Choromańska
Barbara Choromańska
PMPiotr Myśliwiec
Piotr Myśliwiec
Iwona FlisiakIwona Flisiak
Iwona Flisiak
Psoriasis is characterized by hyperproliferation, deregulated differentiation and impaired apoptosis of keratinocytes. Mechanisms of lipid profile disturbances and metabolic syndrome in the psoriatic patients are still not fully understood. Sphingolipids, namely ceramides (CER) and sphingosine-1-phosphate (S1P) are signal molecules which can regulate cell growth, apoptosis and immune reactions. The aim of the study was to evaluate circulating CER and S1P levels in plaque-type psoriasis and their associations with the disease activity, inflammatory or metabolic markers and the presence of psoriatic comorbidities. Eighty-five patients with exacerbated plaque-type psoriasis and thirty-two healthy controls were enrolled. Serum CER and S1P concentrations before the treatment were examined. General patient characteristics included: PASI (Psoriasis Area and Severity Index), BMI (Body Mass Index), inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidities. Total serum concentration of CER was significantly decreased (p = 0.02) and concomitantly S1P levels significantly increased (p = 0.002) in psoriatic patients compared to the healthy control group. Among patients with psoriasis no significant correlations with the disease activity and inflammation markers were observed and only patients with psoriatic arthritis had significantly higher CER total concentration. Serum sphingolipid disturbances in psoriatic patients were observed. Decreased total CER and increased S1P serum levels may reflect their epidermal altered composition and metabolism. Patients with psoriatic arthritis have higher CER levels than psoriasis with skin involvement only. It might provide additional predictive value for psoriatic arthritis and may convey higher risk of metabolic and cardiovascular disease development in this group of patients.